Age (yrs)
|
|
41
(33-56)
|
40
(23-63)
|
66
(57-74)
|
38
(32-44)
|
Gender |
Male |
20 (67%) |
23 (26%) |
10 (40%) |
40
(62%) |
|
Female |
10 (33%) |
65 (74%) |
15 (60%) |
24
(38%) |
Ethnicity |
African |
2 (7%) |
7 (8%) |
0 (0%) |
64
(100%) |
|
Arab |
0 (0%) |
1 (1%) |
0 (0%) |
0 (0%) |
|
Bangladeshi |
1 (3%) |
2 (2%) |
0 (0%) |
0
(0%) |
|
Indian |
7 (23%) |
3 (3%) |
0 (0%) |
0
(0%) |
|
Iraqi |
1 (3%) |
0 (0%) |
0 (0%) |
0 (0%) |
|
Pakistani |
5 (17%) |
3 (3%) |
1 (4%) |
0
(0%) |
|
South East Asian |
2 (7%) |
1 (1%) |
0 (0%) |
0
(0%) |
|
White |
12 (40%) |
66 (75%) |
24 (96%) |
0
(0%) |
|
Unknown |
0 (0%) |
5 (6%) |
0 (0%) |
0
(0%) |
Location of infection |
Pulmonary |
11 (37%) |
- |
- |
51
(80%) |
|
Extrapulmonary |
16 (53%) |
- |
- |
9 (14%) |
|
Both |
3 (10%) |
- |
- |
1 (1%) |
|
Unknown |
0 (0%) |
- |
- |
3 (5%) |
Culture confirmed |
Yes |
20 (67%) |
- |
- |
64
(100%) |
|
No |
10 (33%) |
- |
- |
0 (0%) |
Resistance |
None |
26 (87%) |
- |
- |
- |
|
Isoniazid |
1 (3%) |
- |
- |
- |
|
Pyrazinamide |
2 (7%) |
- |
- |
- |
|
Rifampicin |
0 (0%) |
- |
- |
- |
|
MDR |
1 (3%) |
- |
- |
- |
NTM species |
MAC |
- |
- |
22 (88%) |
- |
|
M. abscessus |
- |
- |
2 (8%) |
- |
|
M. malmoense |
- |
- |
1 (4%) |
- |
Baseline ALT (IU/L)
|
|
18
(14-35)
|
15
(12-21)
|
15
(12-22)
|
20
(14-30)
|
Treatment |
Isoniazid, Rifampicin |
- |
43 (48%) |
- |
- |
|
Isoniazid |
- |
26 (30%) |
- |
- |
|
Rifampicin |
- |
18 (20%) |
- |
- |
|
Moxifloxacin |
- |
1 (1%) |
- |
- |
|
Rifampicin, Azithromycin |
|
- |
1 (4%) |
- |
|
Rifampicin, Clarithromycin |
- |
- |
3 (12%) |
- |
|
Rifampicin, Clarithromycin, Amikacin |
- |
- |
1 (4%) |
- |
|
Rifampicin, Ethambutol |
- |
- |
1 (4%) |
- |
|
Rifampicin, Ethambutol, Amikacin |
- |
- |
1 (4%) |
- |
|
Rifampicin, Ethambutol, Clarithromycin |
- |
- |
15 (60%) |
- |
|
Rifampicin, Ethambutol, Moxifloxacin |
- |
- |
1 (4%) |
- |
|
Rifabutin, Clarithromycin, Moxifloxacin |
- |
- |
1 (4%) |
- |
|
Clarithromycin, Clofazimine, Azithromycin |
- |
- |
1 (4%) |
- |
|
Isoniazid, Rifampicin, Pyrazinamide, Ethambutol plus ART |
- |
- |
- |
64 (100%) |
Initiation phase |
Isoniazid, Rifampicin, Pyrazinamide,
Ethambutol |
22 (73%) |
- |
- |
- |
|
Isoniazid, Rifampicin, Pyrazinamide, Moxifloxacin |
1 (3%) |
- |
- |
- |
|
Isoniazid, Rifampicin, Pyrazinamide, Ethambutol, Moxifloxacin |
1 (3%) |
- |
- |
- |
|
Isoniazid, Rifabutin, Pyrazinamide, Ethambutol |
1 (3%) |
- |
- |
- |
|
Isoniazid, Rifampicin, Ethambutol, Moxifloxacin |
3 (10%) |
- |
- |
- |
|
Rifampicin, Ethambutol, Moxifloxacin |
1 (3%) |
- |
- |
- |
|
Bedaquiline, Clofazimine, Cycloserine |
1 (3%) |
- |
- |
- |
Continuation phase |
Isoniazid, Rifampicin |
20 (67%) |
- |
- |
- |
|
Isoniazid, Rifampicin, Moxifloxacin |
2 (7%) |
- |
- |
- |
|
Isoniazid, Rifampicin, Ethambutol |
2 (7%) |
- |
- |
- |
|
Isoniazid, Rifabutin, Moxifloxacin |
1 (3%) |
- |
- |
- |
|
Isoniazid, Ethambutol, Moxifloxacin |
1 (3%) |
- |
- |
- |
|
Isoniazid, Rifampicin, Pyrazinamide, Ethambutol |
1 (3%) |
- |
- |
- |
|
Rifampicin, Ethambutol, Moxifloxacin |
2 (7%) |
- |
- |
- |
|
Bedaquiline, Clofazimine, Cycloserine |
1 (3%) |
- |
- |
- |